



# TRANSVAC

TRANSVAC2: IMPROVING AND ACCELERATING  
VACCINE DEVELOPMENT IN EUROPE

## NEWSLETTER

### TNA Vaccine Development Services

*OPEN CALL: Submit your application now!*

TRANSVAC2 offers a wide variety of high-quality technical services to support the development of prophylactic and therapeutic vaccines for both **human** and **animal** use. These services are not restricted to **any disease** in particular. Services will be offered **free of charge**, with few exceptions!

**Academic and non-academic research groups**, SMEs and industries can apply!

[Check out TRANSVAC services >>>](#)

Apply [here](#) by **December 15th, 2020**

### TRANSVAC & ENOVA Webinar:

Regulatory information for veterinary vaccine development in the EU and where to find it

18th November 2020, at 10:00 AM (CET)

**Speaker:** Kornelia Grein ([www.kgvetmedconsult.com](http://www.kgvetmedconsult.com))

**Registration:** Please email Falko Apel ([falko.apel@vformulation.org](mailto:falko.apel@vformulation.org)).

### Open Call: Services in focus



[Clinical Trial Support](#)

TRANSVAC2 offers services at advanced development stages, like **Clinical Trial Support**. This service can help you navigate the complicated regulatory landscape by providing necessary information on **regulatory** and **ethical requirements**, as well as access to methodological experts for advice and the review of the **clinical protocols**.

#### ARTICLES INSIDE THIS ISSUE:

---

Open call for TNA Vaccine development Services!

---

Webinar  
Regulatory Information for Veterinary vaccines

---

Services in focus:  
Clinical Trial Support

---

Services in focus (cont.)  
Expression/Production of Vaccine antigens in Adenovirus and MVA vectors

---

Metabolomics profile

---

Metabolomics Imaging by Mass Spectrometry

---

Our Services "in action":  
Studies supported by TRANSVAC2

---

TRANSVAC- DS: New project, new website

# Services in Focus (cont.)



[Expression of Vaccine antigens in Adenovirus and MVA vectors](#)

[Production of GMP compliant Adenovirus and MVA vector\(s\)](#)

The appropriate vector can "make or break" a vaccine candidate. Within, TRANSVAC2, Oxford University offers services to produce **Adenovirus and/or MVA vector(s)** expressing antigen(s) of interest to the user. This is the same system currently under clinical testing as one of the **most advanced SARS-CoV-2 vaccine candidates**.



Universiteit  
Leiden

[Metabolomics profile](#)



[Metabolomics Imaging by Mass Spectrometry](#)

Metabolomic approaches such as **Metabolomics Profiling and Imaging**, offer a window into metabolic mechanisms and immunological alterations induced by a vaccine candidate or adjuvant and can even help identify biosignatures of vaccination status or adverse reactions.

## Our services "in action":

CEA

### Nature 2020

In a study supported by TRANSVAC2, partners at CEA helped elucidate the potential antiviral activity of hydroxychloroquine (HCQ) in vitro and in non-human primates. The study found no antiviral activity nor clinical efficacy of HCQ, regardless of the timing of treatment initiation.

[Check the service related to the paper >>>](#)

IRTA & SSI

### Veterinary Research 2020

Partners at IRTA and SSI compare four different adjuvants differing in their immunological signatures that may enhance efficacy of conserved epitopes used in universal Flu vaccine.

[Check the service related to the paper >>>](#)

UNISI

### Vaccines 2020

TRANSVAC2 Partners at Siena University explore Multiparametric flow cytometry as a particularly suitable tool for deep analysis of immune responses after vaccination.

[Check the service related to the paper >>>](#)

### Frontiers in Immunology 2019

UNISI partners also optimized a protocol for the detection of multifunctional epitope-specific CD4+ T Cells, which are fundamental in the characterization of immune responses to vaccination.

[Check the service related to the paper >>>](#)



## TRANSVAC-DS, Towards a sustainable European vaccine infrastructure

Learn about how TRANSVAC-DS consortium is leading the establishment of a sustainable vaccine infrastructure in Europe. Get to know more about the project and partners on the newly launched [website](#).

